The shift towards digital technologies has been accelerated by the ongoing COVID-19 pandemic, which has forced a number of industries to operate remotely, including the pharmaceutical industry.

GlobalData has conducted a survey to assess the obstacles to successful digital transformation in pharmaceutical companies.Digital Transformation - Obstacles to digital transformation

Obstacles to Digital Transformation

Lack of specific skills and talents was the biggest hurdle for digital transformation as opined by 46% of the survey respondents, followed by organisational silos as opined by 42% of the respondents.

Insufficient funding was voted as the third major obstacle in digital transformation by 40% of the respondents, followed by legacy systems and risk-averse culture by 37% and 35% of the respondents, respectively.

Competing priorities of senior executives and regulation and compliance challenges were each voted by 29% of the respondents as the major obstacles, followed by cyber security and privacy requirements (20%) and IT and business misalignment (20%).

Conflicting corporate strategies was voted as a major obstacle for digital transformation by 17% of the respondents.

The analysis is based on 156 responses received from the Digital Platform and Emerging Technology Survey in Health Care Industry, conducted between 17 September and 06 October 2020.